<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01603043</url>
  </required_header>
  <id_info>
    <org_study_id>C-12-020</org_study_id>
    <nct_id>NCT01603043</nct_id>
  </id_info>
  <brief_title>A Multicenter, Proof-Of-Concept Study Of Intravitreal AL-78898A In Patients With Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)</brief_title>
  <official_title>A Multicenter, Randomized, Single-Masked, Sham-Controlled, Proof-of-Concept Study of Intravitreal AL-78898A in Patients With Bilateral Geographic Atrophy (GA) Associated With Age-Related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to to demonstrate superiority of AL-78898A intravitreal (IVT)
      injections compared to sham injections by assessing mean geographic atrophy (GA) lesion size
      change from baseline at Month 12.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants meeting inclusion/exclusion criteria were randomized in a 2:1 ratio to receive
      AL-78898A or a sham injection. The study eye was assessed before and after each injection to
      ensure that the injection procedure and/or study medication had not endangered the health of
      the eye. The Investigator determined each month whether the patient was eligible to receive
      the next injection. The study was terminated due to a high likelihood that continued
      enrollment would reach the predefined study stopping criteria based upon the number of
      patients with drug deposit formation, which made an assessment of efficacy futile.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Management Decision
  </why_stopped>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in GA Lesion Size at Month 12 as Assessed With FAF Imaging</measure>
    <time_frame>Day 0 (injection visit), Month 12</time_frame>
    <description>Efficacy analysis was not conducted due to the termination of the study prior to the primary and secondary efficacy endpoints and the small number of enrolled patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Yearly GA Lesion Size Growth Rate</measure>
    <time_frame>Baseline (Day 0), up to Month 12</time_frame>
    <description>Efficacy analysis was not conducted due to the termination of the study prior to the primary and secondary efficacy endpoints and the small number of enrolled patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in BCVA at Month 12</measure>
    <time_frame>Baseline (Day 0), Month 12</time_frame>
    <description>Efficacy analysis was not conducted due to the termination of the study prior to the primary and secondary efficacy endpoints and the small number of enrolled patients.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Geographic Atrophy</condition>
  <arm_group>
    <arm_group_label>AL-78898A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 intravitreal injection per month for up to 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Injection</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>1 mock injection per month for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Al-78898A</intervention_name>
    <description>0.400 milligrams (mg) per 50 microliters (μL) administered as an intravitreal injection</description>
    <arm_group_label>AL-78898A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham injection</intervention_name>
    <description>Mock injection administered as an empty hub without needle</description>
    <arm_group_label>Sham Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide informed consent and comply with the protocol.

          -  Diagnosis of bilateral geographic atrophy (GA) of the macula secondary to age-related
             macular degeneration, confirmed within 14 days prior to randomization.

          -  Study eye: Maximum best-corrected visual acuity (BCVA) of 55 letters (20/80 Snellen
             equivalent) and a minimum BCVA of 20 letters (20/400 Snellen equivalent) at screening

          -  BCVA of 20 letters (20/400 Snellen equivalent) or better in the non treated eye at
             screening without conditions other than AMD that, in the opinion of the investigator,
             could cause a rapid loss of vision.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Any history or current evidence of exudative (&quot;wet&quot;) AMD in study eye.

          -  Retinal disease other than AMD in the study eye.

          -  Any ophthalmologic condition in study eye that reduces the clarity of the media and
             that, in the opinion of the Investigator interferes with ophthalmologic examination,
             such as advanced cataract or corneal abnormalities.

          -  Any ophthalmologic condition in study eye that prevents adequate imaging of the retina
             judged by the site or reading center.

          -  A history or current medical diagnosis of glaucoma or ocular hypertension in study
             eye.

          -  Any ophthalmic condition in study eye that may require surgery during the study
             period.

          -  Current ocular or periocular infection in the study eye.

          -  History of any disease or current use of medication expected to cause systemic or
             ocular immunosuppression, such as RESTASIS®.

          -  History of uveitis or endophthalmitis in the study eye.

          -  History of intraocular surgery (including cataract surgery) in the study eye within 90
             days prior to dosing.

          -  History of intravitreal or periocular injection in the study eye at anytime.

          -  Participation in another interventional clinical study, or use of any experimental
             treatment for AMD or any other investigational new drug within 6 weeks or during
             active period of drug (whichever is longer) prior to the start of study treatment.

          -  History of any medical or psychiatric condition, or substance abuse, that in the
             Investigator's opinion is likely to interfere with the patient's participation in the
             study, or likely to cause serious adverse events during the study.

          -  Women of child bearing potential UNLESS they are using a highly effective method of
             birth control.

          -  Known or suspected allergy or hypersensitivity to fluorescein or other injectables.

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehdi Hosseini, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2012</study_first_submitted>
  <study_first_submitted_qc>May 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2012</study_first_posted>
  <results_first_submitted>December 3, 2013</results_first_submitted>
  <results_first_submitted_qc>December 3, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 20, 2014</results_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Geographic Atrophy</keyword>
  <keyword>Age-Related Macular Degeneration</keyword>
  <keyword>Intravitreal injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from 7 study centers located in the United States.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>AL-78898A</title>
          <description>1 intravitreal injection per month for up to 12 months</description>
        </group>
        <group group_id="P2">
          <title>Sham Injection</title>
          <description>1 mock injection per month for 12 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study Futility</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AL-78898A</title>
          <description>1 intravitreal injection per month for up to 12 months</description>
        </group>
        <group group_id="B2">
          <title>Sham Injection</title>
          <description>1 mock injection per month for 12 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in GA Lesion Size at Month 12 as Assessed With FAF Imaging</title>
        <description>Efficacy analysis was not conducted due to the termination of the study prior to the primary and secondary efficacy endpoints and the small number of enrolled patients.</description>
        <time_frame>Day 0 (injection visit), Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AL-78898A</title>
            <description>1 intravitreal injection per month for up to 12 months</description>
          </group>
          <group group_id="O2">
            <title>Sham Injection</title>
            <description>1 mock injection per month for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in GA Lesion Size at Month 12 as Assessed With FAF Imaging</title>
          <description>Efficacy analysis was not conducted due to the termination of the study prior to the primary and secondary efficacy endpoints and the small number of enrolled patients.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Yearly GA Lesion Size Growth Rate</title>
        <description>Efficacy analysis was not conducted due to the termination of the study prior to the primary and secondary efficacy endpoints and the small number of enrolled patients.</description>
        <time_frame>Baseline (Day 0), up to Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AL-78898A</title>
            <description>1 intravitreal injection per month for up to 12 months</description>
          </group>
          <group group_id="O2">
            <title>Sham Injection</title>
            <description>1 mock injection per month for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Yearly GA Lesion Size Growth Rate</title>
          <description>Efficacy analysis was not conducted due to the termination of the study prior to the primary and secondary efficacy endpoints and the small number of enrolled patients.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in BCVA at Month 12</title>
        <description>Efficacy analysis was not conducted due to the termination of the study prior to the primary and secondary efficacy endpoints and the small number of enrolled patients.</description>
        <time_frame>Baseline (Day 0), Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AL-78898A</title>
            <description>1 intravitreal injection per month for up to 12 months</description>
          </group>
          <group group_id="O2">
            <title>Sham Injection</title>
            <description>1 mock injection per month for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in BCVA at Month 12</title>
          <description>Efficacy analysis was not conducted due to the termination of the study prior to the primary and secondary efficacy endpoints and the small number of enrolled patients.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for the duration of the study (6 months). An Adverse Event (AE) was defined as any untoward medical occurrence in a patient administered a study treatment regardless of causal relationship.</time_frame>
      <desc>At each visit, after the patient had the opportunity to spontaneously mention any problems, the Investigator inquired about AEs by asking the standard questions, “Have you had any health problems since your last study visit?” and “Have there been any changes in the medicines you take since your last study visit?”</desc>
      <group_list>
        <group group_id="E1">
          <title>AL-78898A</title>
          <description>1 intravitreal injection per month for up to 12 months</description>
        </group>
        <group group_id="E2">
          <title>Sham Injection</title>
          <description>1 mock injection per month for 12 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Retinal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Product deposit</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Dental implantation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yamini Patel, PhD, Clinical Lead</name_or_title>
      <organization>Alcon Research, Ltd.</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

